ArticleBritish journal of clinical pharmacology2021
Model-informed drug repurposing: Viral kinetic modelling to prioritize rational drug combinations for COVID-19.
Article in British journal of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Model-informed drug repurposing: A pharmacometric approach to novel pathogen preparedness, response and retrospection.British journal of clinical pharmacology · 2021Pooled it
- Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir-ritonavir in patients with COVID-19.British journal of clinical pharmacology · 2026Trial
- Mathematical Modeling of Andrographolide Therapy Effects and Immune Response in In Vivo Dynamics of SARS-CoV-2 Infection.Viruses · 2025Article
- Mathematical modelling of the heterogeneity of disease progression and treatment outcomes in patients with COVID-19.Frontiers in microbiology · 2025Article
- SAAM II: A general mathematical modeling rapid prototyping environment.CPT: pharmacometrics & systems pharmacology · 2024Article
- Drug Cocktail Formulation via Circuit Design.IEEE transactions on molecular, biological, and multi-scale communications · 2023Article
- Article
- Review
- Modeling the disruption of respiratory disease clinical trials by non-pharmaceutical COVID-19 interventions.Nature communications · 2022Article
- Treatment of Respiratory Viral Coinfections.Epidemiologia (Basel, Switzerland) · 2022Article
- Solving the Evidence Interpretability Crisis in Health Technology Assessment: A Role for Mechanistic Models?Frontiers in medical technology · 2022Article
- Model Integration in Computational Biology: The Role of Reproducibility, Credibility and Utility.Frontiers in systems biology · 2022Article
- Science fiction has become reality: Best practice for future viral pandemics.British journal of clinical pharmacology · 2021Article
- Model-informed drug repurposing: Viral kinetic modelling to prioritize rational drug combinations for COVID-19.British journal of clinical pharmacology · 2021Article
- Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.Clinical pharmacology and therapeutics · 2021Review
- Systems and Clinical Pharmacology of COVID-19 Therapeutic Candidates: A Clinical and Translational Medicine Perspective.Journal of pharmaceutical sciences · 2021Article
- Medicinal Plants in COVID-19: Potential and Limitations.Frontiers in pharmacology · 2021Article
- Early Treatment of COVID-19 Disease: A Missed Opportunity.Infectious diseases and therapy · 2020Article
- Clinical trials of disease stages in COVID 19: complicated and often misinterpreted.The Lancet. Global health · 2020Article
- Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19.The American journal of tropical medicine and hygiene · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimWe hypothesized that viral kinetic modelling could be helpful to prioritize rational drug combinations for COVID-19. The aim of this research was to use a viral cell cycle model of SARS-CoV-2 to explore the potential impact drugs, or combinations of drugs, that act at different stages in the viral life cycle might have on various metrics of infection outcome relevant in the early stages of COVID-19 disease.
methodsUsing a target-cell limited model structure that has been used to characterize viral load dynamics from COVID-19 patients, we performed simulations to inform on the combinations of therapeutics targeting specific rate constants. The endpoints and metrics included viral load area under the curve (AUC), duration of viral shedding and epithelial cells infected. Based on the known kinetics of the SARS-CoV-2 life cycle, we rank ordered potential targeted approaches involving repurposed, low-potency agents.
resultsOur simulations suggest that targeting multiple points central to viral replication within infected host cells or release from those cells is a viable strategy for reducing both viral load and host cell infection. In addition, we observed that the time-window opportunity for a therapeutic intervention to effect duration of viral shedding exceeds the effect on sparing epithelial cells from infection or impact on viral load AUC. Furthermore, the impact on reduction on duration of shedding may extend further in patients who exhibit a prolonged shedder phenotype.
conclusionsOur work highlights the use of model-informed drug repurposing approaches to better rationalize effective treatments for COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.